Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pragya Yadav

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Emerging Infectious Diseases|April 20, 2019
Infections among Contacts of Patients with Nipah Virus, IndiaC P Girish Kumar, Attayur P Sugunan, Pragya Yadav, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
BMC Infectious Diseases|April 28, 2025
Protocol for nationwide surveillance of Acute Encephalitis Syndrome (AES) in a network of tertiary care hospitals in IndiaAnoop Velayudhan, Harmanmeet Kaur, Rahul Dhodapkar, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
The Indian Journal of Medical Research|July 3, 2020
Authors' responseNivedita Gupta, Varsha Potdar, Ira Praharaj, et al.
The Indian Journal of Medical Research|April 4, 2020
Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus Research & Diagnostic LaboratoriesNivedita Gupta, Varsha Potdar, Ira Praharaj, et al.
Eclinicalmedicine|April 30, 2026
Oropouche virus: transmission, epidemiology, genetic diversity, and public health implicationsLorenzo Subissi, James R Otieno, Christopher Ruis, et al.
Nature Medicine|July 29, 2025
A systematic nomenclature for mpox viruses causing outbreaks with sustained human-to-human transmissionChristopher Ruis, Eddy Lusamaki, Aine O'Toole, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Emerging Infectious Diseases|April 20, 2019
Infections among Contacts of Patients with Nipah Virus, IndiaC P Girish Kumar, Attayur P Sugunan, Pragya Yadav, et al.
The Lancet. Infectious Diseases|January 24, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trialRaches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, et al.
BMC Infectious Diseases|April 28, 2025
Protocol for nationwide surveillance of Acute Encephalitis Syndrome (AES) in a network of tertiary care hospitals in IndiaAnoop Velayudhan, Harmanmeet Kaur, Rahul Dhodapkar, et al.
The Lancet. Infectious Diseases|March 11, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialRaches Ella, Siddharth Reddy, Harsh Jogdand, et al.
Lancet (London, England)|November 14, 2021
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddarth Reddy, William Blackwelder, et al.
European Urology Oncology|June 10, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single InstitutionHimanshu Nagar, Marshall A Diven, Brady Rippon, et al.
The Indian Journal of Medical Research|July 3, 2020
Authors' responseNivedita Gupta, Varsha Potdar, Ira Praharaj, et al.
The Indian Journal of Medical Research|April 4, 2020
Laboratory preparedness for SARS-CoV-2 testing in India: Harnessing a network of Virus Research & Diagnostic LaboratoriesNivedita Gupta, Varsha Potdar, Ira Praharaj, et al.
Eclinicalmedicine|April 30, 2026
Oropouche virus: transmission, epidemiology, genetic diversity, and public health implicationsLorenzo Subissi, James R Otieno, Christopher Ruis, et al.
Nature Medicine|July 29, 2025
A systematic nomenclature for mpox viruses causing outbreaks with sustained human-to-human transmissionChristopher Ruis, Eddy Lusamaki, Aine O'Toole, et al.
Pageof 8